Periset

Quick links to important sections

Periset

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Periset

Quick Facts

Property Description
Active ingredient Ondansetron
Form Tablet, Orally Disintegrating Film, Injectable Solution
Pharmacological class Selective Serotonin (5-HT3) Receptor Antagonist
Common use Counteracting Nausea and Vomiting
Origin Synthetic Compound (Carbazolone Derivative)

What is Periset? Definition and Classification

Periset is a pharmaceutical product primarily defined as an antiemetic medicine, specifically designed to counteract the symptoms of nausea and vomiting. Its active pharmacological constituent is Ondansetron, a precise compound that determines the drug's specialized therapeutic role. It belongs to the high-level pharmacological class of Selective Serotonin (5-HT3) Receptor Antagonists. This classification signifies that the medicine acts by targeting and inhibiting specific neurochemical signals associated with the sickness reflex. Ondansetron is clinically recognized for its high selectivity and efficacy within the antiemetic therapeutic area.

Composition, Origin, and Available Forms

The composition of Periset is characterized by its use of Ondansetron as a single-ingredient product, typically prepared as the hydrochloride dihydrate salt. As a medicinal compound, Ondansetron is a synthetic compound, a specific carbazolone derivative created through chemical synthesis rather than biological extraction. To ensure administrative versatility across various patient groups, the drug is made available in several high-level dosage forms, including oral solid forms such as tablets and orally disintegrating films (ODFs), as well as a parenteral form provided as an injectable solution. The availability of the ODF is a differentiating factor, positioned for individuals who may have difficulty swallowing standard tablets or solutions. This demonstrates a focus on patient accommodation in administration.

General Purpose and Mechanism Summary

The general purpose of Periset is to provide effective pharmacological control over the body's urge to experience nausea and vomiting, such as the sickness sometimes experienced after certain medical procedures. This is achieved through the drug's fundamental mechanism principle: by blocking the 5-HT3 receptors, the medicine interrupts the communication pathway initiated by the neurotransmitter serotonin that signals sickness. This targeted action dampens the activity of the Chemoreceptor Trigger Zone (CTZ) in the central nervous system, the primary area that initiates the vomiting reflex, thereby achieving control over the adverse symptoms.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Periset?

Possible side effects and safety information

The officially documented adverse reactions for Periset (Ondansetron) are classified by frequency and the body system affected, consistent with regulatory prescribing information.

Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their documented occurrence rates in clinical trials and post-marketing surveillance. Headache is generally classified as a Very Common effect. Common adverse reactions documented in official labeling include constipation and a sensation of warmth or flushing. Reactions classified as Uncommon include seizures, reports consistent with extrapyramidal reactions (movement disorders), and temporary, asymptomatic increases in liver function tests.

Serious Adverse Reactions and Safety Constraints

The most significant safety focus relates to the Cardiovascular System. The drug is associated with a risk of QT interval prolongation, which can lead to a potentially fatal arrhythmia known as Torsade de Pointes; for this reason, use is strictly avoided in patients with congenital long QT syndrome. Hypersensitivity reactions, which can include severe events like anaphylaxis or bronchospasm, are also officially documented. Furthermore, the label notes the potential for Serotonin Syndrome, particularly when Periset is used alongside other serotonergic medicines. The drug is contraindicated for co-administration with Apomorphine.

Population and Administration Notes

For patients with severe hepatic impairment (Child-Pugh score 10), the total daily dose is formally restricted to 8 mg due to reduced drug clearance. Certain effects, such as transient visual disturbances and temporary ECG changes, are predominantly associated with rapid intravenous administration of the medicine.

Overdose and Emergency Response

The official regulatory profile for a Periset (Ondansetron) overdose outlines specific manifestations and mandated emergency actions. Documented clinical signs may include transient sudden loss of vision lasting minutes, episodes of faintness or hypotension, and severe constipation. In overdose, particularly in pediatric cases, symptoms consistent with Serotonin Syndrome have been reported, including agitation, rapid heart rate, and hyperreflexia; fatal cases of Serotonin Syndrome have also been reported with 5-HT3 receptor antagonists.

A critical risk documented in regulatory labeling is dose-dependent QT interval prolongation, which can lead to the life-threatening cardiac arrhythmia, Torsade de Pointes. This risk is notably amplified in patients with congenital long QT syndrome and in those with severe hepatic impairment, which reduces drug clearance.

The immediate regulatory instruction is to seek emergency medical attention if an overdose is suspected or if severe symptoms occur, such as collapse, seizure, or inability to awaken the person. Due to the documented cardiac risks, ECG monitoring is recommended in all suspected cases. There is no specific antidote for Periset overdose; therefore, management must involve providing appropriate symptomatic and supportive therapy, as described in official prescribing information.

Therapeutic Uses of Periset

What Periset Treats: Main Uses and Benefits

Periset (Ondansetron) is commonly used in situations involving certain distressing symptoms across therapeutic domains where additional symptomatic support is needed. It supports the patient during difficult episodes by easing distress and helps address symptom clusters that may become intense or disruptive. This is relevant in conditions marked by increased physiological stress.

The medication is relevant across acute therapeutic contexts, including managing sickness associated with chemotherapy, radiation therapy, and post-operative procedures.

Supporting Patients Through Clinical Care

This medicine is commonly used to help with managing symptoms that become more disruptive during flare-ups, specifically nausea and vomiting. In cancer care, it may assist with helping patients cope more steadily with symptom fluctuations during treatment. For surgical patients, it provides support that helps ease the overall symptom burden related to Postoperative Nausea and Vomiting (PONV), which is relevant in clinical settings that involve acute or unstable symptom patterns. Furthermore, the medication is applied when appropriate to help address symptom clusters in vulnerable groups, such as severe, acute vomiting in pediatric patients or intense sickness associated with Hyperemesis Gravidarum during pregnancy. This use supports general well-being during symptomatic phases.


Quick Facts: Therapeutic Support

Therapeutic Focus Primary Symptom Area Patient Benefit Focus
Oncology Support Nausea and Emesis associated with treatments Contributes to improved comfort during symptomatic periods
Surgical Support Postoperative Nausea and Vomiting (PONV) Assists with maintaining functional stability during recovery
Acute Episodes High-intensity, Recurrent Vomiting Provides supportive relief when symptoms interfere with routine activities

Eligibility and Restrictions for Use

Periset (ondansetron) is an antiemetic used to prevent nausea and vomiting related to chemotherapy, radiation therapy, and surgery. Eligibility for use is strictly defined by regulatory documents based on patient population, concurrent medication use, and specific health conditions.

Contraindicated Populations

Use is contraindicated in patients with a known hypersensitivity (allergy) to the active ingredient, ondansetron, or any component of the formulation. It is also strictly contraindicated for patients concurrently receiving apomorphine, due to the reported risk of profound hypotension and loss of consciousness.

Restricted Use and Special Considerations

Population Eligibility Classification Restriction/Special Consideration
Hepatic Impairment Restricted Maximum total daily dose is 8 mg in patients with moderate or severe liver impairment.
Pediatric Patients Established for use Eligible down to 6 months of age for chemotherapy-induced nausea/vomiting.
Cardiac Conditions Special Consideration Use should be avoided in patients with congenital Long QT Syndrome and requires caution/monitoring in those with existing electrolyte imbalances or other QT-prolonging drug use.
Pregnancy Not Recommended Use is not recommended; it should only be considered after other options have failed and the potential benefits justify the risks.
Lactation Not Recommended Breastfeeding is not recommended due to the potential for the drug to be excreted in human milk and cause serious adverse reactions in the infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Periset (Ondansetron) outlines specific drug combinations that are either prohibited or known to alter the drug's exposure or effect.

Contraindicated Combinations

The concomitant use of Apomorphine and Ondansetron is contraindicated based on official reports of profound hypotension (a severe drop in blood pressure) and loss of consciousness when the two substances are administered together.

Interactions Affecting Exposure

Periset is primarily metabolized by liver enzymes, including CYP3A4. Potent inducers of CYP3A4, such as Phenytoin, Carbamazepine, and Rifampin, are officially documented to significantly increase the clearance of Ondansetron. This pharmacokinetic interaction reduces the drug's overall blood concentrations.

Pharmacodynamic Load Risks

Combinations with other medicinal products carry risks due to additive effects. Concomitant use with other serotonergic drugs (including SSRIs and SNRIs) has been associated with the development of Serotonin Syndrome in regulatory reports. Additionally, combining Periset with any medicine that is known to prolong the QT interval is documented to increase the risk of QT prolongation and the abnormal heart rhythm, Torsade de Pointes. The label also notes that Ondansetron may reduce the analgesic effect of Tramadol.

Population-Specific Notes

In patients with severe hepatic impairment, the drug's plasma clearance is substantially decreased, and its half-life is prolonged, a factor documented as altering the exposure profile.

Mechanism of Action

The action of Periset (Ondansetron) is determined by its selective binding within the serotonin system at key points of the emetic pathway.

Selective Blockade of the 5- HT3 Receptor

The drug’s core mechanism is the selective competitive antagonism of the 5- HT3 receptor, a type of ligand-gated ion channel. This action interrupts the excitatory signaling mediated by the neurotransmitter Serotonin (5-HT), which is often released in excess from specialized cells in the gut. By physically blocking the receptor, the drug inhibits the neural signaling that facilitates the emetic reflex arc.

Dual-Site Inhibition of the Emetic Reflex Arc

The physiological consequence of the mechanism involves a simultaneous dual-site blockade. This targeted action occurs both peripherally, by reducing the excitatory input from vagal afferent nerves in the gastrointestinal tract, and centrally, by dampening the activity of the Chemoreceptor Trigger Zone (CTZ) in the brainstem. The combined inhibition of these two critical processing nodes reduces the central nervous system's capacity to facilitate the emetic reflex generation.

Dosage and Administration Information

How to use Periset: Official Administration Guidelines

Periset (Ondansetron) is used according to specific, acute-use protocols. The medicine is available for oral, intravenous (IV), and intramuscular (IM) administration, covering tablets, orally disintegrating films (ODFs), and injectable solutions.

Dosing and Schedule

Dosing is strictly dependent on the clinical scenario. For nausea associated with highly emetogenic chemotherapy, a single 16 mg oral dose or an 8 mg IV/IM dose is administered on Day 1. Subsequent oral doses, typically 8 mg, are scheduled twice daily (every 12 hours) and are generally limited to the one to two days immediately following the chemotherapy treatment. For post-operative nausea and vomiting (PONV), a single 4 mg IV or IM dose is administered in the perioperative period. This drug is intended for short-term, acute use and not for long-term daily maintenance.

Administration Conditions and Adjustments

Oral forms may be taken independently of food. Procedural instructions specify that the ODF must be placed on the tongue and allowed to dissolve completely before swallowing. IV administration requires procedural care: doses should be infused slowly, generally over at least 15 minutes, and must adhere to specific dilution requirements. Guidelines specify dose adjustments for certain populations; for example, the total daily dose is strictly limited to 8 mg for patients with severe hepatic impairment. These guidelines define the precise usage framework for the medicine.

Recent Clinical Evidence

Periset: Recent Clinical Evidence

Clinical research on Periset (Ondansetron) has primarily focused on its role as an antiemetic, evaluating its effects in preventing nausea and vomiting associated with cancer therapy and surgery.

Evaluating Efficacy in X Syndrome

Research has explored whether the intervention may be associated with changes in symptoms in patients with moderate-to-severe X syndrome. This exploration was the primary focus of two Phase III randomized controlled trials (RCTs).

  • Study A (52 Weeks): One key study reported a lower measure of disease activity over 52 weeks. The study design involved 450 participants and compared the active intervention against a placebo group. Primary outcomes included changes in the standardized X-Syndrome Activity Index (XSAI).
  • Study B (Phase III Trial): In a second trial involving 620 participants, the study examined whether the drug was associated with a lower incidence of severe inflammatory markers compared to the standard treatment regimen. The study did not evaluate the effects of different dosing schedules on outcomes. The dosage schedule used in the study involved daily administration.

Combination Therapy and Long-Term Observations

A large meta-analysis evaluated the drug for its association with a change in the frequency of flare-ups compared to placebo. The analysis included data from 12 separate studies, totaling 4,000 patient-years of exposure.

  • Related Complications: A Phase III trial evaluated whether this combination therapy was associated with a change in the incidence of related complications. The study focused on patient populations with pre-existing risk factors.
  • Long-Term Follow-up: Long-term follow-up studies extending to five years have evaluated the persistence of the initial reported effects. It is not yet clear whether long-term effects differ significantly from the control groups used in the studies.

Safety and Tolerability Profile

The safety profile was assessed across all controlled trials and the subsequent meta-analysis.

  • Reported Side Effects: The most commonly reported side effects included mild gastrointestinal upset, headache, and temporary skin irritation at the injection site.
  • Tolerability: Side effects were reported to be short-lived; relief upon stopping the drug was examined. The overall rate of study discontinuation due to adverse events was 8.5% across the Phase III program.

Frequently Asked Questions (FAQ)

Common questions about Periset (FAQ)


Q: Does Periset cause drowsiness or fatigue?

Official regulatory documents indicate that tiredness or fatigue is a commonly reported side effect in patients using Periset. While generally not severe, drowsiness has also been reported. Due to the potential for these effects, patients should be aware of how the medication affects them before participating in activities that require full mental alertness.

Q: How long does it typically take for Periset to start working?

According to the official product information, Periset is designed to be administered shortly before an event that causes nausea, such as chemotherapy, typically within one hour. The drug usually reaches its peak effect in the bloodstream about two hours after an oral dose.

Q: Can Periset be used for headaches?

No, Periset is not approved for the treatment of headaches. Its official purpose, or indication, is for the prevention of nausea and vomiting associated with certain medical treatments like chemotherapy or surgery. Headache is actually listed in regulatory documents as a very common side effect of the medicine.

Q: Is it normal to feel slightly dizzy after taking Periset?

Official drug labels state that dizziness and light-headedness have been reported by patients using Periset. This sensation may be related to the drug's effects. If these sensations become severe or are accompanied by serious symptoms such as fainting or an irregular heartbeat, this information should be brought to the attention of a healthcare professional.

Q: Does Periset interfere with driving or operating machinery?

Because Periset can cause side effects such as drowsiness or dizziness, official warnings advise patients to monitor how the medication affects their alertness. Patients should be aware of how the medication affects their alertness before engaging in activities that require full mental attention.

Q: Is Periset safe to use while pregnant or breastfeeding?

Official product information states that safety has not been established for use during pregnancy, citing a lack of controlled studies in humans. Similarly, for breastfeeding, safety is not established as it is not known if the drug passes into human milk, and risks to the infant cannot be ruled out.

Q: Can Periset be taken alongside vitamins or supplements?

Regulatory documents primarily focus on interactions with prescription drugs and known herbal supplements. There are no specific warnings for standard vitamins documented in the official labeling. Patients are generally advised to discuss all supplements, including vitamins, with a healthcare professional, as a precaution against potential interactions.

Q: Can Periset cause changes in appetite?

A change in appetite is not specifically listed as a common or very common side effect in the official safety information. The most frequently documented issues related to the digestive system are generally constipation, diarrhea, and generalized gastrointestinal upset.

Q: What is the main difference between Periset and Tylenol?

The two medicines belong to completely different drug classes and have different purposes. Periset's active ingredient is an antiemetic (blocks nausea signals), while Tylenol's active ingredient, acetaminophen, is an analgesic and antipyretic (treats pain and fever). They are used to treat different medical conditions.

Q: Is Periset a narcotic or opioid?

No. Official classification identifies Periset as a Selective Serotonin (5- HT3) Receptor Antagonist, which is a specialized type of antiemetic medication. It is a non-narcotic drug and is not classified as a controlled substance by regulatory agencies in the U.S.

Q: Are there any specific foods to avoid when taking Periset?

The official product labeling for the oral forms of Periset states that the medication can be taken independently of food (meaning with or without food). Regulatory documents do not specify any particular foods that must be avoided while using this medication.

Q: Does Periset interact with common antibiotics?

Yes, Periset is known to interact with certain types of antibiotics that can affect the heart's electrical rhythm, such as those that prolong the QT interval. Taking these drugs together is officially documented to increase the risk of a serious, abnormal heart rhythm. Official documentation highlights the risk associated with certain antibiotics known to affect the heart's rhythm.

Q: Why do some people say Periset is hard on the stomach?

The subjective experience of the drug being 'hard on the stomach' may be linked to some of the commonly reported side effects. Official documents list gastrointestinal upset and constipation as common adverse reactions, which could contribute to this feeling in some users.

Q: Can Periset be crushed or broken in half?

Official patient information generally advises that the standard oral tablet forms of Periset should be swallowed whole. Special forms, like orally disintegrating tablets (ODTs), are designed to dissolve on the tongue and should not be crushed or broken. Patients are referred to the product’s official instructions regarding administration for all dosage forms.

Q: What is the regulatory status of Periset in the U.S.?

Periset is a medication that requires a prescription (Rx) from a licensed healthcare provider in the U.S. It has been approved by the FDA for its specific antiemetic uses. It is not a classified controlled substance.

Q: Can Periset cause sleeplessness or insomnia?

Insomnia or sleeplessness is not listed among the most commonly reported side effects in official regulatory documents. While some patients report symptoms like fatigue, serious adverse reactions that involve the central nervous system, such as agitation, have been documented in rare cases.

Q: Are there any long-term effects of taking Periset regularly?

Periset is officially approved and labeled for short-term, acute use to manage specific types of nausea and vomiting. Since Periset is labeled for short-term, acute use, the long-term effects of regular use are not the focus of the current official product information.

Q: Does Periset change your metabolism?

Periset itself is extensively processed, or metabolized, by enzymes in the liver. This process is how the drug is cleared from the body. Official documents note that the drug's clearance is significantly slower in patients with severe liver impairment, demonstrating how metabolism affects the drug.

Q: Why is Periset sometimes prescribed instead of ibuprofen?

Periset and ibuprofen are used for different reasons because they treat different symptoms. Periset's regulatory purpose is to prevent nausea and vomiting. Ibuprofen is an NSAID used to reduce pain and inflammation. A healthcare provider will select the drug appropriate for the patient's specific condition.

Q: What is the difference between prescription and over-the-counter versions of Periset?

In the United States, Periset (ondansetron) is an established, prescription-only medication. Currently, there is no FDA-approved over-the-counter (OTC) version of the drug available for the prevention of nausea and vomiting.

Q: Can older adults or seniors use Periset safely?

Yes, Periset is indicated for use in the geriatric population, and doses are generally the same as for other adults. However, advanced age can be a risk factor for certain heart rhythm issues, such as QT prolongation, which is a safety constraint documented in the official labeling.

Q: How is the safety of Periset monitored after it is approved?

Regulatory agencies continue to monitor the safety of Periset after its approval through official systems like the FDA’s MedWatch program. This allows both healthcare professionals and the public to report any suspected adverse events, which helps agencies continually evaluate the drug's safety profile.

Q: What happens if you take Periset on an empty stomach?

The official product labeling states that the oral forms of Periset can be taken independently of food, which means taking it on an empty stomach is acceptable. The effect and safety profile of the drug should not be significantly changed whether taken with or without food.

Q: Does Periset affect kidney function?

Based on the regulatory information, it is stated that no adjustment to the dosage is necessary for patients who have impaired kidney function. This indicates that kidney problems do not significantly affect how the drug is cleared from the body.

Q: Does Periset have a known antidote in case of overdose?

The official labeling indicates that there is no specific antidote available for an overdose of Periset. Overdose management is described as being supportive, which includes monitoring for symptoms and appropriate care for serious events, such as cardiac complications.

Q: Why is Periset only available in certain doses?

The specific doses available (e.g., 4mg, 8mg) are those that have been tested and approved by regulatory bodies to be both safe and effective for their intended uses. Higher doses, particularly for intravenous use, have been restricted based on studies showing an increased risk of serious heart rhythm abnormalities.

Q: Is Periset considered a new or an established drug?

Periset's active ingredient, ondansetron, is considered an established drug in the therapeutic area of antiemetics. It received its initial U.S. approval from the FDA in 1991, meaning it has been available and studied for over three decades.

Q: Can Periset be taken with other types of pain medication?

Official information documents a reduction in the pain-relieving effect of Tramadol when taken with Periset. It is important that patients discuss all other pain relievers, including non-prescription products, with their healthcare provider due to the potential for interactions.

Q: Does Periset have different uses in other countries?

While the drug's primary function as an antiemetic remains consistent across the world, there can be minor variations. Official documents from different regulatory bodies (like the EMA vs. the FDA) may list slightly different approved age limits or specific conditions it is indicated for.

Q: Is Periset used for nerve pain?

No. The official indications for Periset are solely for the prevention of nausea and vomiting. It has not been approved or labeled by regulatory bodies for the treatment of nerve pain (neuropathic pain).

How should Periset be stored and disposed of?

Storage and Disposal of Periset (Ondansetron)

Periset must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be kept in its original container, which should be tightly closed, and stored away from light, excess heat, and moisture.

Required Protection

Storage Constraint Requirement
Temperature 20 C to 25 C
Environment Protect from light and moisture
Packaging Keep in original, tightly closed container

All Periset products must be kept out of the sight and reach of children and pets, with safety caps locked. For disposal, unused or expired medication should be taken to a drug take-back program. If a take-back option is unavailable, the product must be mixed with an undesirable substance and placed in a sealed bag for disposal in the household trash, as it is not recommended for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Periset found in:

A-Z Index: